Tags

Type your tag names separated by a space and hit enter

Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events.
Vaccine. 2005 May 09; 23(25):3256-63.V

Abstract

Since 1996, the scientific community has become aware of 14 reports of yellow fever vaccine (YEL)-associated viscerotropic disease (YEL-AVD) cases and four reports of YEL-associated neurotropic disease (YEL-AND) worldwide, changing our understanding of the risks of the vaccine. Based on 722 adverse event reports after YEL submitted to the U.S. Vaccine Adverse Event Reporting System in 1990-2002, we updated the estimates of the age-adjusted reporting rates of serious adverse events, YEL-AVD and YEL-AND. We found that the reporting rates of serious adverse events were significantly higher among vaccinees aged > or =60 years than among those 19-29 years of age (reporting rate ratio = 5.9, 95% CI 1.6-22.2). Yellow fever is a serious and potentially fatal disease. For elderly travelers, the risk for severe illness and death due to yellow fever infection should be balanced against the risk of a serious adverse event due to YEL.

Authors+Show Affiliations

Epidemic Intelligence Service, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, GA, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15837230

Citation

Khromava, Alena Y., et al. "Yellow Fever Vaccine: an Updated Assessment of Advanced Age as a Risk Factor for Serious Adverse Events." Vaccine, vol. 23, no. 25, 2005, pp. 3256-63.
Khromava AY, Eidex RB, Weld LH, et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine. 2005;23(25):3256-63.
Khromava, A. Y., Eidex, R. B., Weld, L. H., Kohl, K. S., Bradshaw, R. D., Chen, R. T., & Cetron, M. S. (2005). Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine, 23(25), 3256-63.
Khromava AY, et al. Yellow Fever Vaccine: an Updated Assessment of Advanced Age as a Risk Factor for Serious Adverse Events. Vaccine. 2005 May 9;23(25):3256-63. PubMed PMID: 15837230.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. AU - Khromava,Alena Y, AU - Eidex,Rachel Barwick, AU - Weld,Leisa H, AU - Kohl,Katrin S, AU - Bradshaw,Robert D, AU - Chen,Robert T, AU - Cetron,Martin S, AU - ,, PY - 2004/07/08/received PY - 2004/11/26/revised PY - 2005/01/05/accepted PY - 2005/4/20/pubmed PY - 2005/6/14/medline PY - 2005/4/20/entrez SP - 3256 EP - 63 JF - Vaccine JO - Vaccine VL - 23 IS - 25 N2 - Since 1996, the scientific community has become aware of 14 reports of yellow fever vaccine (YEL)-associated viscerotropic disease (YEL-AVD) cases and four reports of YEL-associated neurotropic disease (YEL-AND) worldwide, changing our understanding of the risks of the vaccine. Based on 722 adverse event reports after YEL submitted to the U.S. Vaccine Adverse Event Reporting System in 1990-2002, we updated the estimates of the age-adjusted reporting rates of serious adverse events, YEL-AVD and YEL-AND. We found that the reporting rates of serious adverse events were significantly higher among vaccinees aged > or =60 years than among those 19-29 years of age (reporting rate ratio = 5.9, 95% CI 1.6-22.2). Yellow fever is a serious and potentially fatal disease. For elderly travelers, the risk for severe illness and death due to yellow fever infection should be balanced against the risk of a serious adverse event due to YEL. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/15837230/Yellow_fever_vaccine:_an_updated_assessment_of_advanced_age_as_a_risk_factor_for_serious_adverse_events_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(05)00128-3 DB - PRIME DP - Unbound Medicine ER -